Each year, approximately 65,000 Americans are diagnosed with pancreatic cancer, a disease known for its rapid growth and tendency to spread to nearby organs. Even with a comprehensive treatment approach—including surgery, radiotherapy, and chemotherapy—the prognosis remains grim, with a median survival of less than a year. Pancreatic tumors are highly resistant to conventional therapies, and recurrence rates are alarmingly high, highlighting the urgent need for new treatment solutions.
One of the primary challenges in treating pancreatic cancer effectively is the presence of cancer stem cells within the tumor. These resilient cells drive treatment resistance and recurrence due to their ability to self-renew and regenerate the tumor after conventional therapies.
At Acomhal Research, we are working to advance cancer care by developing pioneering therapies aimed at addressing the significant challenges posed by aggressive cancers, including pancreatic cancer, with our innovative drug, a mimetic peptide based on a segment of Cx43, a protein essential for cell-to-cell communication.
